• Original Paper: Sol-gel and hybrid materials for biological and health (medical) applications
  • Published:

Magnetic polyelectrolyte-based composites with dual anticoagulant and thrombolytic properties: towards optimal composition


Magnetic thrombolytic composites are a promising and rapidly developing class of nanostructured bioactive materials with plausible applications in cardiovascular diseases treatment. This class of nanoformulations can be applied to enhance the efficiency of thrombolytic agent delivery in occluded vessels. The main trends in this topic are aimed at the simplification of the composition, enhancement of specific activity, and completeness of action of the formulations. Herein we describe four thrombolytic systems prepared using urokinase-type plasminogen activator (uPA) conjugated to a magnetite core via polyelectrolyte molecules, namely heparin, enoxaparin, polyacrylic acid (PAA) and polystyrene sulfonate (PSS). All systems, except PSS-based, demonstrated close thrombolytic activities when taken in equivalent quantities, while the heparin based system demonstrated 30% greater activity at early stages of clot lysis. Both heparin and enoxaparin-based systems showed moderate anticoagulant activities which prolonged thrombin time from 13 to 17 s that is 3.1 and 1.5-folds lower than for equal amounts of free anticoagulants. The enoxaparin-based formulation inhibited the intrinsic coagulation pathway by 30%, while all other composites were ineffective for this purpose. These findings can be further applied for development of magnetically controlled nanomedicines with dual anticoagulant and thrombolytic properties.


  • Highly stable magnetite hydrosols were synthesized via ultrasonically assisted co-precipitation.

  • Magnetite nanoparticles were decorated with anionic polyelectrolytes and urokinase enzyme.

  • Thrombolytic activity of the systems were evaluated in vitro via Thrombodynamic method.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Benjamin EJ, Virani SS, Callaway CW et al. (2017) Heart disease and stroke statistics—2017 update

  2. 2.

    Moodie DS (2016) The global burden of cardiovascular disease. Congenit Heart Dis 11:213

    Google Scholar 

  3. 3.

    Nichols M, Townsend N, Scarborough P, Rayner M (2013) Cardiovascular disease in Europe: epidemiological update

  4. 4.

    Moser KM, Hajjar GC(1960) The combined use of fibrinolytic and anticoagulant agents. Laboratory and clinical considerations* Am J Cardiol 6:496–502

    CAS  Google Scholar 

  5. 5.

    Manco-Johnson MJ, Nuss R, Hays T et al. (2000) Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 136:446–453

    CAS  Google Scholar 

  6. 6.

    Simoons ML, Krzemiñska-Pakula M, Alonso A et al. (2002) Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction: the AMI-SK study. Eur Heart J 23:1282–1290

    CAS  Google Scholar 

  7. 7.

    Antman EM, Anbe DT, Armstrong PW et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation 110:588–636

    Google Scholar 

  8. 8.

    Théroux P, Welsh RC (2003) Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 91:860–864

    Google Scholar 

  9. 9.

    Zamanlu M, Farhoudi M, Eskandani M et al. (2018) Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. J Drug Target 26:95–109

    CAS  Google Scholar 

  10. 10.

    Colasuonno M, Palange AL, Aid R et al. (2018) Erythrocyte-inspired discoidal polymeric nanoconstructs carrying tissue plasminogen activator for the enhanced lysis of blood clots. ACS Nano 12:12224–12237

    CAS  Google Scholar 

  11. 11.

    Chapurina YE, Drozdov AS, Popov I et al. (2016) Streptokinase@alumina nanoparticles as a promising thrombolytic colloid with prolonged action. J Mater Chem B 4:5921–5928

    CAS  Google Scholar 

  12. 12.

    Voros E, Cho M, Ramirez M et al. (2015) TPA immobilization on iron oxide nanocubes and localized magnetic hyperthermia accelerate blood clot lysis. Adv Funct Mater 25:1709–1718

    CAS  Google Scholar 

  13. 13.

    Jeon JK, Han SM, Min SK, et al (2016) Coulomb nanoradiator-mediated, site-specific thrombolytic proton treatment with a traversing pristine Bragg peak. Sci Rep. https://doi.org/10.1038/srep37848

  14. 14.

    Varna M, Juenet M, Bayles R, et al (2015) Nanomedicine as a strategy to fight thrombotic diseases. Futur Sci OA. https://doi.org/10.4155/fso.15.46

  15. 15.

    Drozdov AS, Vinogradov VV, Dudanov IP, Vinogradov VV (2016) Leach-proof magnetic thrombolytic nanoparticles and coatings of enhanced activity. Sci Rep 6:28199

    Google Scholar 

  16. 16.

    Andreeva YI, Drozdov AS, Avnir D, Vinogradov VV (2018) Enzymatic nanocomposites with radio frequency field-modulated activity. ACS Biomater Sci Eng 4:3962–3967

    CAS  Google Scholar 

  17. 17.

    Ji J, Ji SY, Yang JA et al. (2012) Ultrasound-targeted transfection of tissue-type plasminogen activator gene carried by albumin nanoparticles to dog myocardium to prevent thrombosis after heart mechanical valve replacement. Int J Nanomedicine 7:2911–2919

    CAS  Google Scholar 

  18. 18.

    Vinogradov VV, Drozdov AS, Mingabudinova LR et al. (2018) Composites based on heparin and MIL-101(Fe): The drug releasing depot for anticoagulant therapy and advanced medical nanofabrication. J Mater Chem B 6:2450–2459

    CAS  Google Scholar 

  19. 19.

    Epshtein M, Korin N (2017) Shear targeted drug delivery to stenotic blood vessels. J Biomech 50:217–221.

    Google Scholar 

  20. 20.

    Li C, Du H, Yang A, et al (2017) Thrombosis-responsive thrombolytic coating based on thrombin-degradable tissue plasminogen activator (t-PA) nanocapsules. Adv Funct Mater. https://doi.org/10.1002/adfm.201703934

  21. 21.

    Lippi G, Mattiuzzi C, Favaloro EJ (2013) Novel and emerging therapies: thrombus-targeted fibrinolysis. Semin Thromb Hemost 39:48–58

    CAS  Google Scholar 

  22. 22.

    Roy K, Srivastwa AK, Ghosh CK (2019) Anticoagulant, thrombolytic and antibacterial activities of Euphorbia acruensis latex-mediated bioengineered silver nanoparticles. Green Process Synth 8:590–599

    CAS  Google Scholar 

  23. 23.

    Lateef A, Folarin BI, Oladejo SM et al. (2018) Characterization, antimicrobial, antioxidant, and anticoagulant activities of silver nanoparticles synthesized from Petiveria alliacea L. leaf extract. Prep Biochem Biotechnol 48:646–652

    CAS  Google Scholar 

  24. 24.

    Lateef A, Ojo SA, Folarin BI et al. (2016) Kolanut (Cola nitida) mediated synthesis of silver–gold alloy nanoparticles: antifungal, catalytic, larvicidal and thrombolytic applications. J Clust Sci 27:1561–1577

    CAS  Google Scholar 

  25. 25.

    Gerber A, Bundschuh M, Klingelhofer D, Groneberg DA (2013) Gold nanoparticles: recent aspects for human toxicology. J Occup Med Toxicol 8:32

    Google Scholar 

  26. 26.

    Gao W, Feng X, Pei A et al. (2014) Bioinspired helical microswimmers based on vascular plants. Nano Lett 14:305–310.

    CAS  Google Scholar 

  27. 27.

    Gong D, Cai J, Celi N et al. (2018) Bio-inspired magnetic helical microswimmers made of nickel-plated Spirulina with enhanced propulsion velocity. J Magn Magn Mater 468:148–154

    CAS  Google Scholar 

  28. 28.

    Jeong S, Choi H, Go G et al. (2016) Penetration of an artificial arterial thromboembolism in a live animal using an intravascular therapeutic microrobot system. Med Eng Phys 38:403–410

    Google Scholar 

  29. 29.

    Khalil ISM, Adel A, Mahdy D et al. (2019) Magnetic localization and control of helical robots for clearing superficial blood clots. APL Bioeng 3:026104

    Google Scholar 

  30. 30.

    Daffertshofer M, Gass A, Ringleb P et al. (2005) Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: Increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator - Results of a phase II clinical trial. Stroke 36:1441–1446

    Google Scholar 

  31. 31.

    Netto CGCM, Toma HE, Andrade LH (2013) Superparamagnetic nanoparticles as versatile carriers and supporting materials for enzymes. J Mol Catal. B Enzym 85–86:71–92

    Google Scholar 

  32. 32.

    Ziv O, Lublin-Tennenbaum T, Margel S (2009) Synthesis and characterization of thrombin conjugated γ-Fe 2O3 magnetic nanoparticles for hemostasis. Adv Eng Mater 11:B251–B260

    Google Scholar 

  33. 33.

    Anastasova EI, Prilepskii AY, Fakhardo AF et al. (2018) Magnetite nanocontainers: toward injectable highly magnetic materials for targeted drug delivery. ACS Appl Mater Interfaces 10:30040–30044

    CAS  Google Scholar 

  34. 34.

    Neuberger T, Schöpf B, Hofmann H et al. (2005) Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater 293:483–496

    CAS  Google Scholar 

  35. 35.

    Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021

    CAS  Google Scholar 

  36. 36.

    Figuerola A, Di Corato R, Manna L, Pellegrino T (2010) From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 62:126–143

    CAS  Google Scholar 

  37. 37.

    Márquez F, Herrera GM, Campo T et al. (2012) Preparation of hollow magnetite microspheres and their applications as drugs carriers. Nanoscale Res Lett 7:1–11

    Google Scholar 

  38. 38.

    Anastasova EI, Ivanovski V, Fakhardo AF et al. (2017) A pure magnetite hydrogel: synthesis, properties and possible applications. Soft Matter 13:8651–8660

    CAS  Google Scholar 

  39. 39.

    Drozdov AS, Volodina KV, Vinogradov VV, Vinogradov VV (2015) Biocomposites for wound-healing based on sol-gel magnetite. RSC Adv 5:82992–82997

    CAS  Google Scholar 

  40. 40.

    Cheng R, Huang W, Huang L et al. (2014) Acceleration of tissue plasminogen activator-mediated thrombolysis by magnetically powered nanomotors. ACS Nano 8:7746–7754

    CAS  Google Scholar 

  41. 41.

    Liu M, Pan L, Piao H et al. (2015) Magnetically actuated wormlike nanomotors for controlled cargo release. ACS Appl Mater Interfaces 7:26017–26021

    CAS  Google Scholar 

  42. 42.

    Weissig V, Pettinger TK, Murdock N (2014) Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine 9:4357–4373

    CAS  Google Scholar 

  43. 43.

    Prilepskii AY, Fakhardo AF, Drozdov AS et al. (2018) Urokinase-conjugated magnetite nanoparticles as a promising drug delivery system for targeted thrombolysis: synthesis and preclinical evaluation. ACS Appl Mater Interfaces 10:36764–36775.

    CAS  Google Scholar 

  44. 44.

    Drozdov AS, Ivanovski V, Avnir D, Vinogradov VV (2016) A universal magnetic ferrofluid: Nanomagnetite stable hydrosol with no added dispersants and at neutral pH. J Colloid Interface Sci 468:307–312

    CAS  Google Scholar 

  45. 45.

    Shapovalova OE, Drozdov AS, Bryushkova EA et al. (2018) Room-temperature fabrication of magnetite-boehmite sol-gel composites for heavy metal ions removal. Arab J Chem 13:1933–1944

    Google Scholar 

  46. 46.

    Fadeeva OA, Panteleev MA, Karamzin SS et al. (2010) Thromboplastin immobilized on polystyrene surface exhibits kinetic characteristics close to those for the native protein and activates in vitro blood coagulation similarly to thromboplastin on fibroblasts. Biochem 75:734–743

    CAS  Google Scholar 

  47. 47.

    Bhattacharjee S (2016) DLS and zeta potential - What they are and what they are not? J Control Release 235:337–351

    CAS  Google Scholar 

  48. 48.

    Gracheva MA, Urnova ES, Sinauridze EI et al. (2015) Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Leuk Lymphoma 56:3418–3425

    CAS  Google Scholar 

  49. 49.

    Odziemkowski MS, Schuhmacher TT, Gillham RW, Reardon EJ (1998) Mechanism of oxide film formation on iron in simulating groundwater solutions: Raman spectroscopic studies. Corros Sci 40:371–389

    CAS  Google Scholar 

  50. 50.

    Morimoto T, Yanai H, Nagao M (1976) Infrared spectra of ammonia adsorbed on zinc oxide. J Phys Chem. https://doi.org/10.1021/j100546a010

  51. 51.

    Fareed J, Hoppensteadt D, Walenga J et al. (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin: Implications for clinical practice. Clin Pharmacokinet 42:1043–1057

    CAS  Google Scholar 

  52. 52.

    Boisson C, Gulino D, Jozefonvicz J et al. (1984) Antithrombic properties of insoluble modified polystyrene: Part I. Thromb Res 34:269–276

    CAS  Google Scholar 

  53. 53.

    Dawes J (1988) Measurement of the affinities of heparins, naturally occurring glycosaminoglycans, and other sulfated polymers for antithrombin III and thrombin. Anal Biochem 174:177–186

    CAS  Google Scholar 

  54. 54.

    Monien BH, Desai UR (2005) Antithrombin activation by nonsulfated, non-polysaccharide organic polymer. J Med Chem 48:1269–1273

    CAS  Google Scholar 

  55. 55.

    Monien BH, Cheang KI, Desai UR (2005) Mechanism of poly(acrylic acid) acceleration of antithrombin inhibition of thrombin: Implications for the design of novel heparin mimics. J Med Chem 48:5360–5368

    CAS  Google Scholar 

  56. 56.

    Steitz R, Leiner V, Siebrecht R,V, Klitzing R (2000) Influence of the ionic strength on the structure of polyelectrolyte films at the solid/liquid interface. Colloid Surface A 163:63–70

    CAS  Google Scholar 

  57. 57.

    Glinel K, Moussa A, Jonas AM, Laschewsky A (2002) Influence of polyelectrolyte charge density on the formation of multilayers of strong polyelectrolytes at low ionic strength. Langmuir 18:1408–1412

    CAS  Google Scholar 

  58. 58.

    Stephens RW, Myöhänen HT, Reisberg T et al. (1992) Heparin binding to the urokinase kringle domain. Biochemistry 31:7572–7579

    CAS  Google Scholar 

  59. 59.

    Seregina EA, Nikulina OF, Tsvetaeva NV et al. (2014) Laboratory tests for coagulation system monitoring in a patient with β-thalassemia. Int J Hematol 99:588–596

    Google Scholar 

  60. 60.

    Soshitova NP, Karamzin SS, Balandina AN et al. (2012) Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics. Blood Coagul Fibrinolysis 23:498–507

    Google Scholar 

  61. 61.

    Seregina EA, Tsvetaeva NV, Nikulina OF et al. (2015) Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria. Blood Cells Mol Dis 54:144–150

    CAS  Google Scholar 

  62. 62.

    Panteleev MA, Dashkevich NM, Ataullakhanov FI (2015) Hemostasis and thrombosis beyond biochemistry: Roles of geometry, flow and diffusion. Thromb Res 136:699–711

    CAS  Google Scholar 

  63. 63.

    Ovanesov MV, Ananyeva NM, Panteleev MA et al. (2005) Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: Initiator cells do not regulate spatial growth rate. J Thromb Haemost 3:321–331

    CAS  Google Scholar 

  64. 64.

    Panteleev MA, Ovanesov MV, Kireev DA et al. (2006) Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 90:1489–1500

    CAS  Google Scholar 

  65. 65.

    Parunov LA, Fadeeva OA, Balandina AN et al. (2011) Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: Changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost 9:1825–1834

    CAS  Google Scholar 

  66. 66.

    Balandina AN, Shibeko AM, Kireev DA et al. (2011) Positive feedback loops for factor v and factor vii activation supply sensitivity to local surface tissue factor density during blood coagulation. Biophys J 101:1816–1824

    CAS  Google Scholar 

  67. 67.

    Ovanesov MV, Panteleev MA, Sinauridze EI et al. (2008) Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis 19:743–755

    CAS  Google Scholar 

  68. 68.

    Parunov LA, Soshitova NP, Fadeeva OA et al. (2014) Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: Studies of spatial dynamics of fibrin clot formation in hemophilia A. Thromb Res 133:112–119

    CAS  Google Scholar 

  69. 69.

    Lipets EN, Ataullakhanov FI (2015) Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J. https://doi.org/10.1186/s12959-015-0038-0

  70. 70.

    Sinauridze EI, Kireev DA, Popenko NY et al. (2007) Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97:425–434

    CAS  Google Scholar 

  71. 71.

    Lundqvist M, Stigler J, Elia G et al. (2008) Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 105:14265–14270

    CAS  Google Scholar 

  72. 72.

    Gryshchuk V, Galagan N (2016) Silica nanoparticles effects on blood coagulation proteins and platelets. Biochem Res Int. https://doi.org/10.1155/2016/2959414

  73. 73.

    Sanfins E, Augustsson C, Dahlbäck B et al. (2014) Size-dependent effects of nanoparticles on enzymes in the blood coagulation cascade. Nano Lett 14:4736–4744

    CAS  Google Scholar 

  74. 74.

    Urano T, Serizawa K, Takada Y et al. (1994) Heparin and heparan sulfate enhancement of the inhibitory activity of plasminogen activator inhibitor type 1 toward urokinase type plasminogen activator. Biochim Biophys Acta 1201:217–222. https://doi.org/10.1016/0304-4165(94)90043-4

    CAS  Article  Google Scholar 

Download references


This work was supported by the Russian Science Foundation, grant no. 16-13-00041.

Author information



Corresponding author

Correspondence to V. V. Vinogradov.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Drozdov, A.S., Prilepskii, A.Y., Koltsova, E.M. et al. Magnetic polyelectrolyte-based composites with dual anticoagulant and thrombolytic properties: towards optimal composition. J Sol-Gel Sci Technol 95, 771–782 (2020). https://doi.org/10.1007/s10971-020-05313-z

Download citation


  • Sol-gel
  • magnetite
  • thrombolytics
  • nanocomposite